J E Galvin

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Cognitive change in Parkinson disease
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 20:302-10. 2006
  2. doi request reprint Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Alzheimer Dis Assoc Disord 22:30-8. 2008
  3. ncbi request reprint Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study
    James E Galvin
    Department of Neurology, Alzheimer s Disease Research Center, School of Medicine, Washington University, St Louis, MO 63108, USA
    Arch Neurol 62:758-65. 2005
  4. pmc Psychosocial determinants of intention to screen for Alzheimer's disease
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Alzheimers Dement 4:353-60. 2008
  5. pmc The "portable" CDR: translating the clinical dementia rating interview into a PDA format
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 ForestPark, Suite 130, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 23:44-9. 2009
  6. ncbi request reprint Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra
    James E Galvin
    Departments of Neurology, Anatomy and Neurobiology, Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Acta Neuropathol 112:115-26. 2006
  7. ncbi request reprint Development of a population-based questionnaire to explore psychosocial determinants of screening for memory loss and Alzheimer Disease
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Alzheimer Dis Assoc Disord 20:182-91. 2006
  8. pmc The muscle protein dysferlin accumulates in the Alzheimer brain
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Acta Neuropathol 112:665-71. 2006
  9. ncbi request reprint Clinical phenotype of Parkinson disease dementia
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 67:1605-11. 2006
  10. ncbi request reprint Validity and reliability of the AD8 informant interview in dementia
    James E Galvin
    Departments of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Neurology 67:1942-8. 2006

Research Grants

Detail Information

Publications43

  1. ncbi request reprint Cognitive change in Parkinson disease
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 20:302-10. 2006
    ..This review will examine the clinical, cognitive, neuropsychiatric features of cognitive deficits associated with PD, discuss their pathologic basis and propose avenues for future research...
  2. doi request reprint Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Alzheimer Dis Assoc Disord 22:30-8. 2008
    ..Improved attention may have positive effects on cognitive and functional outcomes for AD patients, although this hypothesis requires further study and validation...
  3. ncbi request reprint Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study
    James E Galvin
    Department of Neurology, Alzheimer s Disease Research Center, School of Medicine, Washington University, St Louis, MO 63108, USA
    Arch Neurol 62:758-65. 2005
    ..To understand the earliest signs of cognitive decline caused by Alzheimer disease (AD) and other illnesses causing dementia, information is needed from well-characterized individuals without dementia studied longitudinally until autopsy...
  4. pmc Psychosocial determinants of intention to screen for Alzheimer's disease
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Alzheimers Dement 4:353-60. 2008
    ..There is little information about how receptive older adults are to discuss memory problems with healthcare providers. Here we test the psychosocial factors explaining older adults' intention to undergo screening for Alzheimer disease (AD)...
  5. pmc The "portable" CDR: translating the clinical dementia rating interview into a PDA format
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 ForestPark, Suite 130, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 23:44-9. 2009
    ....
  6. ncbi request reprint Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra
    James E Galvin
    Departments of Neurology, Anatomy and Neurobiology, Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Acta Neuropathol 112:115-26. 2006
    ..In this review, we discuss the role of the DA metabolite 3,4-dihydroxyphenylacetaldehyde to provide a plausible link between DA production and metabolism, AS aggregation and the pathogenesis of PD...
  7. ncbi request reprint Development of a population-based questionnaire to explore psychosocial determinants of screening for memory loss and Alzheimer Disease
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Alzheimer Dis Assoc Disord 20:182-91. 2006
    ....
  8. pmc The muscle protein dysferlin accumulates in the Alzheimer brain
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Acta Neuropathol 112:665-71. 2006
    ..In muscle, dysferlin plays a role in the repair of muscle membrane damage. The accumulation of dysferlin in the AD brain may be related to the inability of neurons to repair damage due to A beta deposits accumulating in the AD brain...
  9. ncbi request reprint Clinical phenotype of Parkinson disease dementia
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 67:1605-11. 2006
    ..To determine which clinical features best characterize Parkinson disease dementia (PDD), compared with Alzheimer disease (AD) and dementia with Lewy bodies (DLB), and to determine the pathologic basis for PDD...
  10. ncbi request reprint Validity and reliability of the AD8 informant interview in dementia
    James E Galvin
    Departments of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Neurology 67:1942-8. 2006
    ..To establish the validity, reliability, and discriminative properties of the AD8, a brief informant interview to detect dementia, in a clinic sample...
  11. ncbi request reprint Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia
    James E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA
    Arch Neurol 64:725-30. 2007
    ..To test the ability of patients to rate their own cognitive ability using the AD8 compared with informant and clinician ratings of cognitive status...
  12. ncbi request reprint Expression profiling in the aging brain: a perspective
    James E Galvin
    Department of Neurology, Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO 63108, USA
    Ageing Res Rev 4:529-47. 2005
    ....
  13. ncbi request reprint Evaluation of cognitive impairment in older adults: combining brief informant and performance measures
    James E Galvin
    Department of Neurology, Washington University, St Louis, Missouri 63108, USA
    Arch Neurol 64:718-24. 2007
    ..To combine the AD8, a brief informant interview, with performance measures to develop a brief screening tool to improve detection of cognitive impairment and dementia in general practice...
  14. ncbi request reprint The AD8: a brief informant interview to detect dementia
    J E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University, St Louis, MO 63108, USA
    Neurology 65:559-64. 2005
    ..Brief measures that accurately discriminate normal cognitive aging from very mild dementia are lacking. Cognitive tests often are insensitive to very mild dementia. Informant-based measures may be more sensitive in detecting early dementia...
  15. ncbi request reprint Synucleinopathies: clinical and pathological implications
    J E Galvin
    Alzheimer s Disease Research Center, Department of Neurology, Campus Box 8111, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
    Arch Neurol 58:186-90. 2001
    ..Furthermore, these efforts will likely lead to novel diagnostic and therapeutic strategies in regard to the synucleinopathies...
  16. pmc Lewy body dementia: caregiver burden and unmet needs
    James E Galvin
    Department of Neurology, Washington University, St Louis, MO, USA
    Alzheimer Dis Assoc Disord 24:177-81. 2010
    ..Community resources such as the Lewy Body Dementia Association may serve this end, while also providing practical information and support for caregivers...
  17. ncbi request reprint Familial dementia with Lewy bodies: clinicopathologic analysis of two kindreds
    J E Galvin
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 59:1079-82. 2002
    ..Familial DLB is clinically heterogeneous and occurs with or without coexistent AD, suggesting the relevance of LB pathology for the developing dementia...
  18. ncbi request reprint Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 68:1895-901. 2007
    ..To identify personality traits that distinguish dementia with Lewy bodies (DLB) from Alzheimer disease (AD)...
  19. ncbi request reprint Dementia with Lewy bodies
    James E Galvin
    Alzheimer s Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Arch Neurol 60:1332-5. 2003
  20. ncbi request reprint Neurodegenerative diseases: pathology and the advantage of single-cell profiling
    James E Galvin
    Alzheimer s Disease Research Center, Department of Neurology and Anatomy, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Neurochem Res 29:1041-51. 2004
    ..The pathologic features of neurodegenerative diseases are first discussed followed by a rationale behind sampling mRNA species from single cells rather than from whole-brain homogenates to explore disease mechanisms...
  21. ncbi request reprint Expression profiling and pharmacotherapeutic development in the central nervous system
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 18:264-9. 2004
    ..This is a difficult task that demands a multidisciplinary approach that is highlighted in this review within the context of neurodegenerative pathology...
  22. pmc Predictors of physician referral for patient recruitment to Alzheimer disease clinical trials
    James E Galvin
    Department of Neurology, Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Alzheimer Dis Assoc Disord 23:352-6. 2009
    ..The majority of dementia patients are first evaluated by community-based physicians; however, physician perceptions of clinical research are largely unknown...
  23. ncbi request reprint The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs
    J M Burns
    Department of Neurology, Washington University, St Louis, MO, USA
    Neurology 64:1397-403. 2005
    ..Extrapyramidal signs (EPS) are common in Alzheimer disease (AD) and increase in prevalence as AD advances. The neuropathologic substrate responsible for EPS in AD remains to be fully characterized...
  24. pmc Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology
    J E Galvin
    Department of Neurology, Medical College of Pennsylvania Hahnemann University the Center for Neurodegenerative Disease Research, and the Department of Neurology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Am J Pathol 157:361-8. 2000
    ..These findings expand the concept of neurodegenerative synucleinopathies by implicating alphaS, betaS, and gammaS in the pathogenesis of NBIA 1...
  25. pmc Cognitive profiles in dementia: Alzheimer disease vs healthy brain aging
    D K Johnson
    Alzheimer Disease Research Center, Washington University, St Louis, MO 63108, USA
    Neurology 71:1783-9. 2008
    ..To re-examine proposed models of cognitive test performance that concluded separate factor structures were required for people with Alzheimer disease (AD) and older adults without dementia...
  26. pmc Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
    J E Galvin
    Department of Neurology, Medical College of Pennsylvania, Hahnemann University, 245 North 15th Street, Philadelphia, PA 19129, USA
    Proc Natl Acad Sci U S A 96:13450-5. 1999
    ..Our findings broaden the concept of neurodegenerative "synucleinopathies" by implicating betaS and gammaS, in addition to alphaS, in the onset/progression of PD and DLB...
  27. ncbi request reprint Verbal and visuospatial deficits in dementia with Lewy bodies
    David K Johnson
    Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63108, USA
    Neurology 65:1232-8. 2005
    ..To investigate the cognitive decline in dementia with Lewy bodies (DLBs) and characterize the contribution of Lewy bodies (LBs) to cognitive impairment in the presence of concurrent Alzheimer disease (AD)...
  28. pmc Relationship of dementia screening tests with biomarkers of Alzheimer's disease
    James E Galvin
    Alzheimer s Disease Research Centre, Washington University, St Louis, MO 63108, USA
    Brain 133:3290-300. 2010
    ....
  29. pmc Effect of cognitive fluctuation on neuropsychological performance in aging and dementia
    Adriana Escandon
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Neurology 74:210-7. 2010
    ..Fluctuations are a core feature of dementia with Lewy bodies, but the impact of fluctuations in healthy brain aging and Alzheimer disease (AD) are unknown...
  30. pmc Longitudinal study of the transition from healthy aging to Alzheimer disease
    David K Johnson
    Department of Psychology, University of Kansas, Lawrence, Kansas City, Missouri, USA
    Arch Neurol 66:1254-9. 2009
    ..Detection of the earliest cognitive changes signifying Alzheimer disease is difficult...
  31. ncbi request reprint Distinguishing Lewy body dementias from Alzheimer's disease
    Rawan Tarawneh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Expert Rev Neurother 7:1499-516. 2007
    ..Improved understanding of disease mechanisms may open new therapeutic avenues for LBD in the future...
  32. ncbi request reprint Neuroanatomical predictors of response to donepezil therapy in patients with dementia
    John G Csernansky
    Alzheimer s Disease Research Center, and Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Neurol 62:1718-22. 2005
    ..Patients with dementia of the Alzheimer type (DAT) respond variably to treatment with acetylcholinesterase inhibitors...
  33. ncbi request reprint Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra
    J E Galvin
    Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Exp Neurol 168:347-55. 2001
    ....
  34. ncbi request reprint Detection of aggregates and protein inclusions by staining of tissues
    James E Galvin
    The Alzheimer s Disease Research Center, Department of Neurology, The Washington University School of Medicine, St Louis, MO, USA
    Methods Mol Biol 232:149-64. 2003
  35. ncbi request reprint DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers
    C F Lippa
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Neurology 68:812-9. 2007
    ....
  36. ncbi request reprint Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
    Monique M Williams
    Department of Medicine, Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park, Suite 130, St Louis, MO 63108, USA
    Neurology 67:1935-41. 2006
    ..To determine whether dementia with Lewy bodies (DLB) progresses more rapidly than Alzheimer disease (AD)...
  37. pmc Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
    Joseph F Quinn
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 304:1903-11. 2010
    ..Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology...
  38. ncbi request reprint Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine
    William J Burke
    Department of Neurology, Saint Louis VAMC and Saint Louis University Health Sciences Center, St Louis, MO 63125, USA
    Acta Neuropathol 115:193-203. 2008
    ..Our findings support the hypothesis that DA metabolism via DOPAL can cause both DA neuron loss and AS aggregation observed in PD...
  39. pmc Potential future neuroprotective therapies for neurodegenerative disorders and stroke
    Rawan Tarawneh
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Avenue, Suite 130, St Louis, MO 63108, USA
    Clin Geriatr Med 26:125-47. 2010
    ..Although most of these therapies are experimental, and require further investigation, a few seem to offer promise...
  40. ncbi request reprint The alpha-synuclein mutation E46K promotes aggregation in cultured cells
    Neeraj Pandey
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63108, USA
    Exp Neurol 197:515-20. 2006
    ..Our results demonstrate that mutations in 4th KTKEGV repeat lead to higher propensity of aggregation of AS compared to other mutants...
  41. pmc Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease
    Laurent Seugnet
    Washington University School of Medicine, St Louis, MO 63110, USA
    Sleep 32:984-92. 2009
    ..Thus we investigated the long-term consequences of sleep deprivation on shortterm memory using a Drosophila model of Parkinson disease...
  42. pmc Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  43. ncbi request reprint Pass the grain; spare the brain
    James E Galvin
    Neurology 69:1072-3. 2007

Research Grants1

  1. Dementia of Parkinson Type: Clinicopathologic Phenotype
    James Galvin; Fiscal Year: 2004
    ..At the completion of the award period, candidate plans to develop an independent R01 project derived from the data generated by the experiments described in this proposal. ..